Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNKP | Q96T60 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22000595 | 0.82 | PNKP (1.00) | PNKP | |
| SCHEMBL22001040 | 0.82 | PNKP (1.00) | PNKP | |
| SCHEMBL22000583 | 0.62 | PNKP (1.00) | PNKP | |
| SCHEMBL2876902 | 0.62 | KMT2A (0.44) | — | |
| SCHEMBL18416408 | 0.62 | TRPV1 (0.43) | — | |
| SCHEMBL17186202 | 0.62 | TRPV1 (0.43) | — | |
| SCHEMBL22683129 | 0.61 | PNKP (0.44) | PNKP | |
| SCHEMBL797945 | 0.60 | MAPT (0.43) | — | |
| SCHEMBL797946 | 0.60 | MAPT (0.43) | — | |
| SCHEMBL15303011 | 0.59 | TRPV1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040916-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040916-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010075282-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | UNIVERSITY OF WASHINGTON (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040916-A1 | MOLECULAR INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | WNT1, CTNNB1, WNT3A | PNKP 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.